Difference between revisions of "Part:BBa K4361301"
Line 27: | Line 27: | ||
<html> | <html> | ||
<h3>Usage and Biology</h3> | <h3>Usage and Biology</h3> | ||
− | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 2</u>), a band | + | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 2</u>), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an <i> E. coli </i> cell-free system was successful for this mutant. |
<figure> | <figure> | ||
<a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-2.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-2.png" style="width:600px;margin-left:125px"></a> | <a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-2.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-2.png" style="width:600px;margin-left:125px"></a> | ||
− | <figcaption> <b>Figure 1.</b> SDS PAGE | + | <figcaption> <b>Figure 1.</b> SDS PAGE showing the translation products of 20 different plasmids coding for BlcR mutants. PURE reaction solution was supplemented with GreenLys and the synthesized proteins were imaged with Typhoon using a 488-nm laser. C: negative control with no plasmid. WT: positive control with expressed wildtype BlcR. 2: D37V mutant </figcaption> |
</figure> | </figure> | ||
Revision as of 15:40, 12 October 2022
BlcR D37V
A mutant of the BlcR protein, created through site-directed mutagenesis with primers R1 (Part:BBa_K4361200) and F1.2 D37V (Part:BBa_K4361202). For this mutant, the aspartic acid in position 37 has been changed to valine by mutating the GAC codon to GTG.
This mutant also contains the following nucleotide mutations outside of the targeted site:
- A 50 > C, silent mutation
- G 166 > T, resulting in substitution D56Y
- G 237 > A, silent mutation
- A 341 > C, resulting in substitution H114P
- G 404 > T, resulting in substitution G135V
- G 416 > T, resulting in substitution S139I
Sequencing data only contained this part's sequence up until and including nucleotide 421. All nucleotides after are presumed to be identical to those found in the original codon optimized BlcR, Part:BBa_K4361100.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 694
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 78
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 589
Usage and Biology
The set of BlcR mutants (Part:BBa_K4361300 through Part:BBa_K4361319) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (Figure 1.) to determine whether or not the protein was produced. For this mutant (lane 2), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an E. coli cell-free system was successful for this mutant.